Overview

To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation

Status:
Not yet recruiting

Trial end date:
2024-02-01

Target enrollment:
0

Participant gender:
All

Summary

To evaluate the clinical success rate of micafungin in preventing invasive mycosis after liver transplantation.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Treatments:

Caspofungin
Micafungin

Criteria

Inclusion Criteria:

1. Sign the informed consent form voluntarily;

2. Liver transplant patients with 1 high-risk factor; A. Transplant again; B. Fulminant
liver failure; C. Renal failure requires alternative treatment (defined as creatinine
clearance ≤40 ml/min); D. ICU duration before liver transplantation≥48h; E. Have
received abdominal surgery within one month before liver transplantation or; F. Common
bile duct jejunostomy (except for children); G. Excessive blood transfusion (blood
transfusion exceeds 2000mL); H. The donor's ICU hospital stay exceeds 5 days; I.
Positive sputum and blood culture of the donor J. The donor has evidence of lung or
bloodstream infection (pulmonary infection is evaluated according to the diagnostic
criteria and treatment principles (draft) of invasive lung fungal infection, and
bloodstream infection is evaluated according to invasive fungal disease of patients
with hematopathy/malignant tumor Diagnostic criteria and treatment principles (fifth
revised edition) for evaluation) K. 60 years old ≤ age ≤ 65 years old

Exclusion Criteria:

1. Have used other investigational drugs or are participating in other clinical trials
within 4 weeks before enrollment;

2. Currently combined with any kind of fungal infection;

3. Allergic to study drugs;

4. Joint transplantation;

5. Women who are pregnant, preparing to become pregnant or breast-feeding;

6. The investigator thinks that it is not suitable to use the test drug.